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Purpose: Although sexuality has been reported to be impaired in females with congenital adrenal
hyperplasia (CAH) resulting from 21-hydroxylase deficiency, sexuality in males with CAH so far has
remained largely unconsidered.
Patients: One of the largest European male cohorts of patients with CAH in which sexuality in male
patients with CAH was assessed.
Methods: Sexuality was evaluated in 91 sexually active male patients with CAH using questionnaires
investigating sexual orientation, age at sexual initiation, sexual activity, satisfaction with sex life, and
sexual problems, such as fears or dislike of sexual activity, lack or excessive sexual desire, difficulties
getting aroused or reaching an orgasm, premature ejaculation, and no or incomplete erection.
Results: Sexuality in male patients with CAH was similar to European reference populations. If
sexuality problems were present, they were less frequently reported by the most severely affected CAH
males. Adducing a holistic perspective, sexual problems showed substantial association to psychological
problems, such as anxiety and depression.
Conclusions: Sexuality in male patients with CAH in general was unaffected and sexuality problems
seemed to be associated in particular with psychological problems. Because sexual health is a key factor
Abbreviations: 21OHD, 21-hydroxylase deficiency; CAH, congenital adrenal hyperplasia; DSD, disorder/difference of sex develop-
ment; HADS, Hospital Anxiety and Depression Scale; QoL, quality of life; SV, simple-viralizing; SW, salt-wasting.
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of general health, we recommend that sexuality as well as psychological issues explicitly should be
addressed in health care of patients with a CAH diagnosis, independent of sex.
Copyright © 2019 Endocrine Society
This article has been published under the terms of the Creative Commons Attribution Non-
Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-
nd/4.0/).
Freeform/Key Words: congenital adrenal hyperplasia, 21-hydroxylase deficiency, male,
hormone concentration, sexuality
Congenital adrenal hyperplasia (CAH) comprises a group of autosomal recessive dis-
orders involving altered steroid biosynthesis. The majority of cases with CAH (.95%) are
caused by 21-hydroxylase deficiency (21OHD) [1–3]. 21OHD is clinically classified
according to the severity into the salt-wasting (SW) and simple-virilizing (SV) form, both
classic CAH, with an incidence of 1:10,000 to 15,000, and nonclassic CAH with an in-
cidence of 1:2500 [4]. The second most frequent cause of CAH, 11-hydroxylase deficiency,
has an incidence of 1:200,000, whereas other enzymatic defects affecting adrenal hor-
mone synthesis are very rare [2]. Classic CAH is characterized by cortisol deficiency,
aldosterone deficiency in SW, and subsequent androgen excess. Patients with classic
CAH therefore require lifelong replacement therapy with glucocorticoids and often
also with mineralocorticoids to normalize or suppress the androgen production in the
adrenals [5–7].
Sexuality is an integral part of human development involving biological, physical,
social, and emotional factors. Biological and physical factors focus on the reproductive
function of sexuality, which is mainly influenced by physical development [8]. Social and
emotional factors of sexuality can be separated in cultural background and individual
social experiences (e.g., being influenced by sociocultural norms, psychological well-
being, and individual experiences of attachment and intimacy) [9–12]. A definition of
sexuality covers several categories, including sexual orientation, sexual roles, sexual
temperament, sexual drive and function, sexual beliefs, values, and roles [9, 13, 14].
Sexual function and quality of life (QoL) are interrelated [15]. If sexual function is
impaired by illness, medical therapy, anxiety, or other stress factors, QoL may decline
[14]. QoL in male patients with CAH is reported in a few small studies and varies from
impaired [3, 16, 17] to equal [18] or better [19] compared with a control population,
recently reviewed in Daae et al. [20].
The impact of CAH on the development of the biological and social sex characteristics
varies substantially between the sexes. Prenatal androgen excess can cause virilization of
the external genitalia in females with CAH and is therefore classified as a “disorder/
difference of sex development” (DSD). Androgen excess in females can result in altered
body, behavior, and sexuality [21–25]. Although the physical effect of (prenatal) androgen
excess in male patients with severe 21OHD is not as profound, it might lead to hyper-
pigmentation of the external genitalia, but not to sex incongruence as seen in females
with classic CAH. One study reported no effect of androgen excess on behavior in males
with CAH, because no differences in sexual interest and orientation were found com-
pared with healthy controls [23]. Sexual drive and function were studied in a few small
studies. Impaired sexual drive, erection, and ejaculation was found in one study of 20
males with CAH [26], whereas two other studies described high rates of erectile dys-
function (41% to 55%) and lower sexual activity, which were linked to limited endocrine
control or to oversubstitution with glucocorticoids [3, 18].
The data on sexuality in males with CAH are thus scarce and derived from studies with
small sample sizes in a single center or country. Our aim is to describe sexuality and
factors related to subjective health status, anxiety, and depression in males with CAH in a
large European, multicenter cohort.
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1. Subjects and Methods
A. Subjects
The study cohort was recruited and examined within the collaborative international European
study dsd-LIFE [27]. This study involved 14 medical recruitment centers specialized in
treatment of DSD located in France (n5 4), Germany (n5 4), Poland (n5 2), Sweden (n5 1),
the Netherlands (n 5 2), and the United Kingdom (n 5 1). Between February 2014 and
September 2015, 1040 current and former patientswith a diagnosis ofDSDwere recruited [27].
In addition to the patients with DSD, 121 male patients with CAH were recruited. This group
faces similar problems as patientswithDSD, such as infertility or sex hormone imbalances, but
they do not fit into the DSD classification. We subsequently excluded 30 males with CAH
[median age, 21; interquartile range (IQR), 17.8-33.3; range, 16-64) in this study from further
analysis because they were not sexually active and/or used testosterone preparations or had
CYP11B1 mutations. Thus, 91 males with CAH were included in the current study. Ethical
approvals were obtained for each participating center. All participants gave written informed
consent. Study participation implied filling out digital patient-reported outcome question-
naires and answering medical questionnaires, whereas medical examination was optional.
Participants were examined at their local DSD center. All medical data were pseudonymized
and reviewed on data quality for accuracy of statements. Theoretical and methodological
details of the framework of dsd-LIFE have been published elsewhere [27].
B. General Patient Characteristics
General patient characteristics included age, height, body mass index, severity of disease,
medication use and control, education level, and hormone concentrations. Severity of disease
was classified both clinically and genetically. The phenotype of 21OHD was classified into
SW, SV, or nonclassic CAH. The genetic classification of 21OHD was performed according to
the severity of themutation of the least affected allele reflecting the enzymatic defect (disease
severity), ranging from genotype “0” for the most severe defects to genotype “C” the least
severe defects [28, 29]. Current glucocorticoid and mineralocorticoid replacement therapy
formulations were registered. Hormonal control was assessed by a subjective rating of the
local examining physician at study inclusion using the following scores: poor, moderate, good,
excellent, or unknown. The patients’ educational levels were established according to the EU
classification as low, medium, and high as described elsewhere [30]. The following hormones
were measured in blood samples taken during daytime, mostly in the morning, before intake
of the glucocorticoid medication [27]: androstenedione, total testosterone, LH, and FSH. The
values were assessed by the study centers according to the local reference ranges as “below
reference range,” “within reference range,” “above reference range up to twice the upper
limit,” and “more than twice the upper limit of the reference range.”To increase the number of
patients per category, we combined the latter two categories into the category “above ref-
erence range.” The serum androstenedione/testosterone ratio was calculated and divided into
previously described ranges: ,0.5 (normal, interpreted as testosterone mainly of testicular
origin), $0.5 and ,1 (substantial fraction of testosterone is of adrenal origin), and $1
(testosterone mainly of adrenal origin) [31].
C. Sexuality
Sexual orientation was administered using an adapted Kinsey scale [24, 25]. We defined the
following categories: homosexual (“exclusively to men without desire for women,” “primarily to
men, occasionally to women”), bisexual (“equally to men and women,” “primarily to women, but
also regularly tomen,” “primarily tomen, but also regularly to women”), heterosexual (“primarily
to women, but occasionally to men,” “exclusively to women, without desire for men”), and other
(“primarily to an intersex/transgender/genderqueer/other person”) and “to no one.” Participants
were asked to indicate if they had sexual experience at all, such as intercourse and/or oral sex, and
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were asked on their age of sexual debut. Sexual activity within the past 12 months was divided
into categories: “no sexual activity or once/twice a year,” “once to twice amonth,” and “once/twice a
week or nearly daily.” The World Health Organization QoL-BREF item “How satisfied are you
with your sex life?” [32] was used to address sexual satisfactions within the past 12 months,
using a 5-point Likert scale. To increase the number of participants within each group, we
combined the groups very (dis)satisfied with (dis)satisfied. We assessed psychosexual is-
sues, including lack of or excessive sexual desire; in getting aroused or in reaching orgasm,
fears or dislike of sexual activity or contact, or premature ejaculation and no or incomplete
erection, by asking participants if they experienced these problems of not.
D. Psychological Parameters
Self-perceived (subjective) health status was measured by the European Social Survey item
“How is your health in general,” using a 5-point Likert scale. Mental health conditions that
are likely to affect sexuality are anxiety and depression [33–36]. Therefore, we used the
Hospital Anxiety and Depression Scale (HADS), a widely used short self-rating and
screening instrument [37]. The HADS contains two scales about anxiety (seven items) and
depression (seven items), each with a 4-point Likert scale [37]. Cutoff points established by
the authors of the scale for self-reported anxiety or depression were: 0 to 7 “normal” (below
clinical cutoff), 8 to 10 “borderline abnormal” (borderline range), and $11 “abnormal”
(above clinical cutoff).
E. Statistics
Statistical analysis was performed using IBM SPSS Statistics 25. Descriptive analyses
were performed for all variables. Depending on normality, mean and 95%CIs ormedian and
IQRs were calculated. Patients with and without sexuality problems were compared and
ORs with 95% CIs were calculated if at least five cases were present in both subgroups.
Missing data were evaluated for each variable and the total number of participants in a
particular analysis is reported. Data resources can be requested from the Steering Com-
mittee and the coordinator of the project dsd-LIFE.
2. Results
Table 1 shows the basic characteristics of 91 sexually active menwith 21OHD.Median age was
30 years. Most of the participants had the classical form of CAH, the SW (58.2%), or SV
(35.2%) forms, whereas 5.5% had nonclassical CAH. Patients were also classified genet-
ically into genotype 0 (19.8%), A (27.5%), B (28.6%), C (3.3%), or could not be classified
(20.8%). The majority of participants used only hydrocortisone as glucocorticoid treat-
ment (58.2%). Prednisone or prednisolone was used by 25.3% of the participants, whereas
11.0% used dexamethasone alone or in combination with hydrocortisone. No intake of
glucocorticoid replacement at all was reported by 3.3% of the participants. Educational
background was of intermediate level for 54.4% of the participants, whereas 26.7% had
high and 8.9% had low educational level, and 10.0% were classified as other. Testosterone
concentrations were within normal reference range for 77.3% of the cohort, 17.3% were
below and 5.3% above the reference range. The majority of the cohort estimated their
health status as very good (25.3%) or good (51.6%). Furthermore, the majority of par-
ticipants scored below the clinical cutoff level for mental health problems as depression
(92.3%) and anxiety (74.7%) (i.e., did not have mental health problems). Still, one-fourth of
the cohort scored above the clinical cutoff level for anxiety.
We analyzed all variables mentioned in the “Patients and Methods” section, but we only
present in detail the data that differed between the analyzed groups (no overlap in confidence
intervals). In the following sections, we present data regarding sexuality in males with CAH.
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A. Sexuality
Heterosexuality was reported in 90.1%, homosexuality in 3.3%, and bisexual orientation in
1.1%. Furthermore, 2.2% of the participants reported to be attracted to the category “other”
and 3.3% reported not to be sexually attracted (Table 2). Median age of sexual initiation was
17 years. More than one-half of the participants (58.4%) reported to be sexually active weekly
or monthly and satisfaction with sex life was expressed to be neutral to satisfying. Sexual
problems, including fear of sexual activities (4.4%), dislike of sexual activities (4.4%), lack of
Table 1. Cohort Description of Sexually Active Male Patients With 21-Hydroxylase Deficiency (N 5 91)
Parameter Cohort Results
Median age (IQR; range) 30 y (23–41; 16–68)
Height, mean (95% CI), n 5 90 170.8 cm (169.3–172.4)
BMI, median (IQR), n 5 90 25.6 kg/m2 (22.6–29.9)
Severity of the disease, n 5 91
Clinical classification
Classic: SW 53 (58.2%)
Classic: SV 32 (35.2%)
Nonclassic 5 (5.5%)
No clinical classification 1 (1.1%)
Genetic classification
0 18 (19.8%)
A 25 (27.5%)
B 26 (28.6%)
C 3 (3.3%)
No mutation reported or not classified 19 (20.8%)
Medication, n 5 91
Hydrocortisone 53 (58.2%)
Prednisone or prednisolonea 23 (25.3%)
Dexamethasone or hydrocortisone and
dexamethasoneb
10 (11.0%)
Fludrocortisone in addition to any of the
glucocorticoid combinations here
62 (68.1%)
Fludrocortisone alone 2 (2.2%)
No medication reported 3 (3.3%)
Education, n 5 90
High 24 (26.7%)
Intermediate 49 (54.4%)
Low 8 (8.9%)
Other 9 (10.0%)
Total testosterone concentrations, n 5 85
Above reference range 4 (5.3%)
Within reference range 58 (77.3%)
Below reference range 13 (17.3%)
Subjective health status, n 5 91
Bad 5 (5.5%)
Fair 16 (17.6%)
Good 47 (51.6%)
Very good 23 (25.3%)
HADS-anxiety, n 5 91
Normal 68 (74.7%)
Borderline abnormal 7 (7.7%)
Abnormal 16 (17.6%)
HADS-depression, n 5 91
Normal 84 (92.3%)
Borderline abnormal 2 (2.2%)
Abnormal 5 (5.5%)
Abbreviation: BMI, body mass index.
aEleven patients were on prednisolone, 11 on prednisone, and 1 on prednisone retard.
bDexamethasone was used combined with hydrocortisone in 3 patients, whereas 7 patients were on dexamethasone.
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sexual desire (17.6%) or excessive sexual desire (23.1%), difficulties in getting aroused
(12.1%), difficulties reaching an orgasm (11.0%), premature ejaculation (25.3%), and no or
incomplete erection (18.7%), were reported.
B. Influencing Parameters on Sexuality in Males With CAH
The frequency of sexual activity was associated with genotype, medication control, and
depression (Table 3). Participants with genotype 0 were less likely to have monthly sexual
activity than participants with genotype A (OR, 0.125; 95% CI, 0.016 to 0.999). Participants
with genotype Awere less likely to havemonthly (OR, 0.111; 95%CI, 0.016 to 0.778) or weekly
(OR, 0.167; 95% CI, 0.030 to 0.917) sexual activity than participants with genotype B.
Participants with moderate compared with good subjective therapy (glucocorticoid) con-
trol were more likely (OR, 4.1; 95% CI, 1.0 to 16.4) to have weekly sexual activity than
monthly sexual activity. Weekly was less common compared with monthly sexual activity for
Table 2. Sexuality in Sexually Active Male Patients With 21-Hydroxylase Deficiency
Parameter Cohort Result
Normal Population
Results Details Reference
Sexual orientation, n 5 91
Heterosexual 82 (90.1%) 94.2% Males and females
from the UK, .16 y
[38]
Homosexual 3 (3.3%) 0.9%
Bisexual 1 (1.1%) 0.5%
Other 2 (2.2%) 0.5%
To no one 3 (3.3%) No response: 3.2%
Age at sexual debut,
median (range), n 5 80
17 y (16–18) Mean: 16.5 y Males and females
from the EU, 16–20 y
[41]
Sexual activity, n 5 91
Nearly daily
and 1–2/wk
37 (44.3%) Study 1: 1.4/wk Males from SE, 18–60 y [42]
1–2/mo 24 (22.6%) Study 2: 1.9/wk Males from FR, .35 y [43]
1–2/y and no sexual
activity in past y
7 (6.6%)
No sexual partner 28 (26.4%)
Satisfaction with
sex life, n 5 91a
3.5 6 1.1 3.7 6 1.31 Males from SE, 18–60 y [42]
Fears of sexual
activities, n 5 91
4 (4.4%)
Dislike of sexual
activities, n 5 91
4 (4.4%)
Lack of sexual
desire, n 5 91
16 (17.6%) Study 1: 11.97% Males from EU, 40–80 y [44]
Study 2: 11.7%–15.7% Males from ES and DE, 55 y [49]
Excessive sexual
desire, n 5 91
21 (23.1%) 5%–10% Males from SE, 18–60 y [42]
Difficulties getting
aroused, n 5 91
11 (12.1%)
Difficulties reaching an
orgasm, n 5 91
10 (11.0%)
Premature
ejaculation, n 5 91
23 (25.3%) Study 1: 20.2% Males from EU, 40–80 y [44]
Study 2: 20%–20.3% Males from IT and DE, 41.6 y [51]
Study 3: 25%–40% Males (global), all ages [52]
Study 4: 3%–30% International: all ages [33, 53]
No or incomplete
erection, n 5 91
17 (18.7%) Study 1: 12.5% Males from EU, 40–80 y [44]
Study 2: 12% Males from DE, UK, FR, 52.6 y [50]
Study 3: 17.4% Males from IT, ES, 20–75 y [49]
Study 4: 23% Males from DE, 18–79 y [48]
Abbreviations: DE, Germany; ES, Spain; EU, European Union; FR, France; IT, Italy; SE, Sweden; UK, United
Kingdom.
aSelf-reported satisfaction with sexual life rated on a 5-point Likert scale from very dissatisfied (1) to very satisfied (5).
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participants with “borderline abnormal” depression scores compared with “normal” scores
(OR, 0.102; 95% CI, 0.011 to 0.979). Satisfaction with sex life was not associated with any of
the variables tested. Both lack (OR, 0.266; 95% CI, 0.080 to 0.885) and excessive (OR, 0.296;
95% CI, 0.105 to 0.837) sexual desire were associated with phenotype, with SV being more
affected with these issues compared with men with SW CAH. Excessive sexual desire was
more likely to be observed in participantswith clinical anxiety scores comparedwith “normal”
scores (OR, 28.0; 95% CI, 3.1 to 254.5) and compared with “borderline abnormal” anxiety
scores (OR, 26.0; 95% CI, 2.2 to 304.7). Participants with SW CAH had more difficulties
getting aroused (OR, 0.122; 95% CI, 0.016 to 0.960) compared with participants with non-
classic CAH, and more difficulties reaching an orgasm (OR, 0.170; 95% CI, 0.032 to 0.901)
compared with participants with SV CAH. Participants with “abnormal” anxiety scores also
had more difficulties reaching an orgasm compared with participants with “normal” scores
(OR, 12.0; 95%CI, 2.0 to 73.0). Furthermore, participants with “borderline abnormal” anxiety
scores also reported premature ejaculation more often compared with participants with
Table 3. Parameters Associated With Sexuality in Sexual Active Male Patients With 21-
Hydroxylase Deficiency
Characteristics Outcome OR
Frequency of sexual activity
Genotype Monthly NA Null vs B: 0.125
Null 3 (33.3%) 6 (66.6%) (0.016–0.999);
A 4 (30.8%) 9 (69.2%) A vs B: 0.111
B 8 (80%) 2 (20%) (0.016–0.778)
Weekly NA 0.167 (0.030–0.917)
A 12 (57.1%) 9 (42.9%)
B 16 (88.9%) 2 (11.1%)
Medication control Weekly Monthly
Moderate 16 (84.2%) 3 (15.8%) 4.1 (1.0–16.4)
Good 21 (56.8%) 16 (43.2%)
HADS-depression Weekly Monthly
Borderline abnormal 1 (20%) 4 (80%) 0.102 (0.011–0.979)
Normal 44 (71%) 18 (29%)
Lack of sexual desire Yes No
Phenotype SW 5 (9.4%) 48 (90.6%) 0.266 (0.080–0.885)
SV 9 (28.1%) 23 (71.9%)
Excessive sexual desire
Phenotype SW 8 (15.1%) 45 (84.9%) 0.296 (0.105–0.837)
SV 12 (37.5%) 20 (62.5%)
HADS-anxiety Abnormal 6 (85.7%) 1 (14.3%) 28.0 (3.1–254.5)
Normal 12 (17.6%) 56 (82.4%)
HADS-anxiety Abnormal 6 (85.7%) 1 (14.3%) 26.0 (2.2–304.7)
Borderline abnormal 3 (18.8%) 13 (81.3%)
Difficulties getting aroused
Phenotype SW 4 (7.5%) 49 (92.5%) 0.122 (0.016–0.960)
NC 2 (40%) 3 (60%)
Difficulties reaching an orgasm
Phenotype SW 2 (3.8%) 51 (96.2%) 0.170 (0.032–0.901)
SV 6 (18.8%) 26 (81.3%)
HADS-anxiety Abnormal 3 (42.9%) 4 (57.1%) 12.0 (2.0–73.0)
Normal 4 (5.9%) 64 (94.1%)
Premature ejaculation
HADS-anxiety Borderline abnormal 7 (46.7%) 8 (53.3%) 3.6 (1.1–11.6)
Normal 13 (19.7%) 53 (80.3%)
Presentation of data that differed between groups (no overlap in CIs); associations are presented through ORs.
Frequency of sexual activity: NA (1–2 times per y and none), monthly (1–2 times per mo), weekly (1–2 times per wk
and nearly daily).
Abbreviations: NA, not applicable; NC, nonclassic CAH; SW, salt-wasting CAH; SV, simple-virilizing CAH.
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“normal” scores (OR, 3.6; 95% CI, 1.1 to 11.6). No associations were found between no or
incomplete erection and any of the variables tested. None of the tested hormones nor the
androstenedione/testosterone ratio were associated with sexuality.
3. Discussion
Studies on sexuality in males with CAH have been scarce. This study describes sexuality in a
large international cohort of males with CAH. In general, we found that sexuality in males
with CAH is comparable to available reference populations as discussed below.
Sexuality in our cohort was assessed using a number of different parameters. The vast
majority of our males with CAHwere heterosexual and the distribution of sexual orientation
was similar to UKmales and females [38], although seemingly a slightly higher proportion of
homosexuality and bisexuality was observed in our cohort. This is somewhat in contrast to
previous studies of males with CAH, which did not observe differences in sexual orientation
compared with control groups [23, 39, 40]. The age of sexual debut was similar to reported
European reference populations [41], which is in line with other reports [39]. The frequency of
sexual activity in the general population was on average 1.4 times a week in Sweden [42] and
1.9 times a week in France [43]. Although we did not have data to calculate the average
number of sexual activities per week, we showed that more than one-half of the males with
CAHwith a sexual partner had nearly daily or at least one to two sexual activities per week. A
substantial frequency number of the “other half” of sexually active males within the cohort
could not be shown (one to two times per month, per year, or none at all). A previous study
found that frequency of intercourse was similar in males with CAH and matched controls
[39]. The males in our study were generally satisfied with their sex life, with a comparable
score to reference population [32, 42]. A minority of males with CAH reported sexual
problems. Only four participants reported fears or dislike of sexual activities. However, lack
of sexual desire as well as excessive sexual desire were present in about one-quarter of the
participants. These sexual problems were more prevalent in our males with CAH compared
with the European male reference cohort (lack of sexual desire) [42, 44], which supports the
findings of Dudzinska et al. [26]. Ten percent of our cohort also experienced difficulties
getting aroused or reaching an orgasm; however, no reference data were available. The
frequency of premature ejaculation problems in our cohort was slightly higher compared with
European reference data (25% vs 20%); also, erectile dysfunctions was found to be slightly
more prevalent in males with CAH (18.7% vs 16.2%), supporting the findings of Dudzinska
et al. [26], Arlt et al. [3], and Falhammar et al. [18]. In conclusion, our cohort of males with
CAH diagnosis, which was recruited through highly specialized European centers, showed
mostly good hormonal control and similar sexuality compared with European reference
populations. In general, sexual problems were not frequently reported, although sexual
desire problems appeared to be more frequent in males with CAH compared with European
reference studies.
Data from our cohort indicate that genotype were associated with the frequency of sexual
activity, meaning that being more severely affected was associated with lower frequency of
sexual activity. In contrast, having moderate therapy control, as opposed to good control, was
associatedwithmore frequent sexual activity. A negative association between depression and
sexual activity was also observed, indicating that when people experience depressive
symptoms, they engage less in sexual activities. However, frequency of sexual activity is
dependent on a variety of factors, such as willingness of both partners. These factors were not
included in our dataset, which makes it difficult to interpret our univariate analyses re-
garding sexual frequency. CAH phenotype was associated with sexual problems regarding
sexual drive. Participants with SW CAH were less likely to report lack of sexual desire,
difficulties in reaching an orgasm, and difficulties in sexual arousal. This is similar to other
reports [18, 26]. Psychological problems can have a major impact on sexuality. We showed
that participants with anxietymore often had excessive sexual desire, difficulties reaching an
orgasm, and premature ejaculation. This may confirm that anxiety is one of the main
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determinants of erectile function disorders in men, or that men with erectile function dis-
orders might show more anxiety [33, 45–47].
Sexuality is an essential part of human life involving physical and herewith biological and
hormonal as well as psychological and emotional factors. As such, it can affect general well-
being and overall QoL. This is also true for chronic diseases, such as CAH, because chronic
diseases influence everyday life and self-perception of patients. Looking at the large cohort of
dsd-LIFE, we can conclude that sexual problems of this groupmainly seemed to be associated
with psychological problems. Still, sexual problems were associated with the severity of the
CAH diagnosis.
A. Limitations
Despite this being a large study describing sexuality in male patients with CAH, it had some
limitations. Subgroup analysis resulted in low numbers of participants, especially those with
aberrant values regarding psychological symptoms. Serum hormone concentrations were not
measured centrally but were determined in each treatment center with different assays and
different reference ranges. Accounting for this, only range variables were used in the data
analyses. Furthermore, sexuality is an integral part of human identity and is influenced by
many aspects, such as sociocultural norms, psychological well-being, and individual expe-
rience of attachment and intimacy [9–12]; although we tried to include as much information
as possible, we did not have information on sexual self-esteem or on relationship satisfaction
that would have given a much more complete picture on sexual QoL [47].
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